Skip to main content
ENDO 2026 Main banner

Stephen R. Hammes, PhD,MD

Chief, Div of Endo & Metabolism
University of Rochester
Rochester, NY, United States

Stephen Hammes, MD, PhD is the Louis S. Wolk Distinguised Professor and the Chief of Endocrinology at the University of Rochester Medical Center. Dr. Hammes received his undergraduate degree in chemistry from Cornell University, followed by his M.D. and Ph.D. in Microbiology and Immunology from Duke University. Dr. Hammes then moved to the University of California in San Francisco (UCSF), where he completed his residency in General Medicine, followed by a fellowship in Endocrinology. Dr. Hammes then joined the faculty at the University of Texas Southwestern Medical Center in Dallas, where he was a W.W. Caruth Scholar in Biomedical Research and Co-Director of the Endocrinology Fellowship program. Dr. Hammes moved to the University of Rochester in 2009 to become the Louis S. Wolk Distinguished Professor of Medicine and the Chief of the Division of Endocrinology, Diabetes, and Metabolism. In addition to serving at the Endocrinology Fellowship Program Director for several years at Rochester, Dr. Hammes is currently the Executive Vice Chair in the Department of Medicine at the University of Rochester.
Dr. Hammes has served as Editor-in-Chief of the scientific journals “Molecular Endocrinology” and “Endocrinology,” and is currently Deputy Editor of the “Journal of the Endocrine Society.” He is a member of the American Society for Clinical Investigation, actively serves on N.I.H. and D.O.D. study sections, serves on the LAM Foundation Board of Directors, and is Past President of the Endocrine Society.
Dr. Hammes’ research interests include steroidogenesis and steroid signaling, with a focus on extranuclear, or nongenomic, steroid effects. He studies these processes in the context of female reproduction, where his lab has demonstrated the importance of androgen signaling in normal ovarian function. In addition, the Hammes lab studies steroid hormone signaling in hormone-sensitive cancers such as prostate cancer and lymphangioleiomyomatosis (LAM).

Disclosure information not submitted.

Presentation(s):